SyntheX uses synthetic biology to create the next generation of drug discovery platforms. Using genetically engineered circuits, we rely on intracellular drug selection as opposed to in-vitro screening. This allows us to discover unbiased compounds with novel modes of action that can engage targets in either competitive or allosteric ways. We have developed ToRPPIDO to discover disruptors of protein-protein interactions (PPIs), and ToRNeDO to discover functional molecular glues for degraders of a neosubstrate of interest with a desired E3 ligase.
In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner.
Our lead programs focus on oncology.
In the same cells, we incorporate our proprietary DNA-encoded libraries of peptides and macrocycles to enable the production and selection of molecules in an efficient and high throughput manner.
Our lead programs focus on oncology.
Location: United States, California, San Francisco
Employees: 11-50
Founded date: 2016
Investors 3
| Date | Name | Website |
| - | MBC BioLab... | mbcbiolabs... |
| - | OMX Ventur... | omx.vc |
| - | Endless Fr... | endlessfro... |
Mentions in press and media 3
| Date | Title | Description |
| 25.04.2019 | The venture firm SOSV has already raised its biggest fund to date, and it isn’t quite closed | SOSV, a multi-stage venture firm that was founded as the personal investing vehicle of entrepreneur Sean O’Sullivan after his company went public in 1994, then re-launched as a traditional venture firm with outside backers in 2015, has rais... |
| 12.07.2016 | Watch the Indiebio Demo Day here | TechCrunch is pleased to bring you Indiebio’s Demo Day this Thursday, July 14th from San Francisco. Backed by SOSV, Indiebio is the largest life sciences accelerator to date. Indiebio provides each startup in the accelerator with $250,000, ... |
| - | SyntheX | “At SyntheX, we are relying on our unique screening platforms, ToRPPIDO and ToRNeDO, to discover and design drugs that target previously undruggable proteins.” |